AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32471891
Drug: CHIPS administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHIPS administration
Trial: 33789251
Drug: Anthocyanins (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins (AC) 320 mg/day in the form of Medox® capsules for 28 days
Trial: 33882052
Drug: Daily e-cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily e-cigarette use
Trial: 33882052
Drug: Daily heated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily heated tobacco use
Trial: 33882052
Drug: Odds of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odds of daily cigarette smoking
Trial: 33882052
Drug: Odds of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odds of daily heated tobacco use
Trial: 36585491
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (ET)
Trial: 35343187
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg
Trial: 35286913
Drug: MW032 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MW032 (120 mg)
Trial: 34959872
Drug: O2-water enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2-water enriched by injection (110 mg O2·L-1)
Trial: 34959872
Drug: O2-water enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2-water enriched by electrolysis (110 mg O2·L-1)
Trial: 34959872
Drug: Placebo water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo water (10 mg O2·L-1)
Trial: 33862286
Drug: Task-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-based training along with conventional therapy
Trial: 32753637
Drug: L-Theanine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Theanine (2.5 mg/kg)
Trial: 32753637
Drug: Caffeine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.0 mg/kg)
Trial: 32753637
Drug: L-Theanine-caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Theanine-caffeine combination
Trial: 36150238
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (2.5 mL orally every 8 hours for 1 month)
Trial: 35430674
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 5.6 mmol/L
Trial: 35430674
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 6.1 mmol/L
Trial: 35430674
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin treatment with fasting blood glucose (FBG) target of > 3.9 to ≤ 7.0 mmol/L
Trial: 35430674
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin treatment
Trial: 32224987
Drug: Tryptophan and
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan and magnesium-enriched Mediterranean diet (60 mg of TRY and 60 mg of MG)
Trial: 38631835
Drug: Stimulant
RxNorm normalized name: Stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant
Trial: 34049443
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine collaborative model of care (TCMCMC) with acupuncture
Trial: 35799299
Drug: Antenatal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal milk expression (AME) intervention involving technique demonstration and feedback from a lactation consultant, daily independent practice, delivered at weekly visits at 37-40 weeks of pregnancy.
Trial: 33879065
Drug: Internet-based behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based behavioural activation (iBA) therapy, 12 weekly sessions with online assignments and feedback from trained therapists.
Trial: 33879065
Drug: Internet-based behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based behavioural activation (iBA) therapy
Trial: 32196826
Drug: Altered fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altered fractionation (AF) - 1.1 Gy + 2 Gy/d, 5 d/wk, 4.5 weeks, total dose 68 Gy
Trial: 32196826
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (CF) - 2 Gy/d, 5 d/wk, 7 weeks, total dose 68 Gy
Trial: 34733978
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment applied at Baihui (GV20), Yintang (GV29), Shenmen (HT7, bilateral), and Sanyinjiao (SP6, bilateral) 3 times a week for 4 weeks.
Trial: 33706653
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (SC‐I)
Trial: 33706653
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (IV‐I)
Trial: 32324850
Drug: Community-based mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based mass testing and treatment (MTaT) performed 3 times per year for 2 years.
Trial: 32324850
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard of care for testing and treatment at public health facilities along with government‐sponsored mass long‐lasting insecticidal net [LLIN] distributions).
Trial: 33793580
Drug: União Química
FDA approved: no
EMA approved: no
PMDA approved: no
Description: União Química generic warfarin
Trial: 33793580
Drug: Teuto generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teuto generic warfarin
Trial: 36057254
Drug: Square-stepping exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Square-stepping exercise (SSE), 8 weeks, twice a week
Trial: 33415872
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) applied at Zusanli (ST 36), Xuehai (SP 10), Sanyinjiao (SP 6) for 30 min each time, twice daily for 5 days.
Trial: 33415872
Drug: Conventional nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional nursing combined with early functional exercise (20 min each time, twice daily for 5 days).
Trial: 33415872
Drug: Rehabilitation training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation training (20 min each time, twice daily for 5 days).
Trial: 33098678
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation (HDR, 45 + 18 Gy)
Trial: 33098678
Drug: Radiochemotherapy (RCT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiochemotherapy (RCT, 45 Gy + 5FU infusion)
Trial: 35571974
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT), provided monthly for up to six months
Trial: 35201924
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology (30 minutes twice per week for 6 weeks)
Trial: 35349976
Drug: High-dose minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose minocycline (10 mg/kg)
Trial: 35349953
Drug: PIO-5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIO-5 (5 mg PIO/bird/day)
Trial: 35349953
Drug: PIO-10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIO-10 (10 mg PIO/bird/day)
Trial: 36415112
Drug: Berberine triple
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine triple therapy (berberine, amoxicillin, rabeprazole)
Trial: 36415112
Drug: Standard bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bismuth quadruple therapy (amoxicillin, rabeprazole, clarithromycin, bismuth tartrate)
Trial: 32654080
Drug: All urate-lowering
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All urate-lowering therapies (ULTs)
Trial: 32654080
Drug: Febuxostat 80/120/240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80/120/240 mg/day
Trial: 32654080
Drug: Lesinurad in
RxNorm normalized name: Product containing lesinurad in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad in combination with febuxostat or allopurinol
Trial: 34636463
Drug: Djulis functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Djulis functional drinks (50 ml daily for 8 weeks)
Trial: 34636463
Drug: Placebo drinks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drinks (50 ml daily for 8 weeks)
Trial: 34103473
Drug: High-dose hUC-MSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hUC-MSC (1.5 × 10^6/kg body weight)
Trial: 34103473
Drug: Low-dose hUC-MSC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hUC-MSC (0.5 × 10^6/kg body weight)
Trial: 34103473
Drug: Low-dose hUC-MSC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hUC-MSC
Trial: 32333337
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) - 24 sessions, 810 nm, 5 diodes × 200 mW, 30 J/application site
Trial: 32333337
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - no physical therapy intervention, only underwent hemodialysis (HD) sessions
Trial: 35030634
Drug: Historical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical treatments (CORAL study)
Trial: 36480560
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg/day) for 6 months
Trial: 35610318
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion with loading dose group (GpIII)
Trial: 35610318
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion without loading dose group (GpII)
Trial: 34243738
Drug: PathMate2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PathMate2 group (PM) - daily conversational agent counselling via mobile app, combined with standardized counselling (4 on-site visits) for 5.5 months.
Trial: 33278291
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with 4 mg dexamethasone
Trial: 36414947
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1000 mg natural fish oil soft-gels daily for 3 months)
Trial: 36414947
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil soft-gels (control group)
Trial: 34694261
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium channel blockers (CCB)
Trial: 33954933
Drug: Oral abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral abrocitinib 200 mg
Trial: 33954933
Drug: Oral abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral abrocitinib 100 mg
Trial: 32172686
Drug: Spiritual coping
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiritual coping through adherence measures (interview or daily phone diary)
Trial: 32481332
Drug: Tong Jing
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tong Jing Tiao Xing tuina (TJTX) once a day, Excising with scalp acupuncture (ESA) once a day, and oral Yinao fujian formula (YNFJ) twice a day for 5 sessions a week for 4 weeks.
Trial: 32481332
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) for 5 sessions a week for 4 weeks.
Trial: 33922576
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose strawberry powder (32 g/day)
Trial: 33922576
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose strawberry powder (13 g/day)
Trial: 32004568
Drug: Bermekimab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bermekimab (400 mg weekly for 13 doses) in anti-TNF naïve patients (n = 18)
Trial: 32004568
Drug: Bermekimab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bermekimab (400 mg weekly for 13 doses) in patients who failed anti-TNF therapy (n = 24)
Trial: 35580634
Drug: Oral phenazopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phenazopyridine (200 mg taken 1 to 2 hours preprocedure)
Trial: 35580634
Drug: Intravesical lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical lidocaine (20-minute instillation of 50 mL of 2% lidocaine)
Trial: 32141476
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bip.App and Group PE
Trial: 35802142
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg OD
Trial: 33827421
Drug: Concurrent magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent magnesium with sodium valproate (group B)
Trial: 36038015
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.2 mg nicotine/cigarette)
Trial: 36038015
Drug: Usual Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual Nicotine Content (UNC) cigarettes (11.6 mg nicotine/cigarette)
Trial: 35759325
Drug: Therapeutic adherence
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic adherence and competence scale for grief (TACs-G)
Trial: 32365981
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299v with 20 mg of iron
Trial: 32365981
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of iron alone
Trial: 35761383
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg per os 2 hours before surgery
Trial: 35761383
Drug: Starch tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch tablet per os 2 hours before surgery (control group)
Trial: 32197636
Drug: Adjunct low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunct low-dose continuous infusion of ketamine (2 μg/kg/min for the first 24 hours, then 1 μg/kg/min for the second 24 hours) plus standard of care.
Trial: 36134443
Drug: App-guided fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-guided fluid therapy calculations
Trial: 36134443
Drug: App-guided integrated
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: App-guided integrated fluid therapy plans
Trial: 32858228
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids 1000 mg/day (EPA+DHA, ratio 1:2)
Trial: 38804148
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg per day
Trial: 32527389
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .04 g/dl
Trial: 32527389
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose of .065 g/dl
Trial: 32527389
Drug: Alcohol doses
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol doses (.04 g/dl and .065 g/dl)
Trial: 36328822
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy
Trial: 33317481
Drug: Health qigong-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health qigong-based cognitive therapy
Trial: 37393402
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 24 weeks
Trial: 37393402
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then bepirovirsen 150 mg for 12 weeks
Trial: 37393402
Drug: Bepirovirsen 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen 300 mg (with 300 mg loading dose) for 12 weeks then placebo for 12 weeks
Trial: 37393402
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks (with placebo loading dose) then bepirovirsen 300 mg without loading dose for 12 weeks
Trial: 86099028
Drug: D-penicillamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine and prednisone (low-dose combination therapy)
Trial: 32091466
Drug: Daily nonlinear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nonlinear periodization (NLP)
Trial: 32091466
Drug: Flexible daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible daily nonlinear periodization (FNLP)
Trial: 33566465
Drug: Enoxaparin started
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2–0.5 international units/mL
Trial: 32169923
Drug: Standardised self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised self-management kits and Usual treatment (Control)
Trial: 32960464
Drug: G‐MEDSS with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐MEDSS with usual care HMR
Trial: 32574657
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention (four sessions)
Trial: 32557974
Drug: HDM sublingual
RxNorm normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM sublingual immunotherapy (SLIT)
Trial: 33832089
Drug: COPD medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD medical treatment + KT (Group 1)
Trial: 33832089
Drug: COPD medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD medical treatment alone (Group 2)
Trial: 32376313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of an intrauterine device (IUD) with a Foley catheter after hysteroscopic adhesiolysis
Trial: 34955257
Drug: Low compound
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low compound probiotics (0.12 g per head per day)
Trial: 34955257
Drug: High compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High compound probiotics (1.2 g per head per day)
Trial: 34955257
Drug: Compound probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound probiotics (both low and high)
Trial: 34955257
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (milk replacer with no compound probiotics)
Trial: 32910710
Drug: Continuous nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nivolumab (3 mg/kg every 2 weeks)
Trial: 36269184
Drug: Repeated low-level
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated low-level red light (RLRL) therapy